Cantor Fitzgerald Reaffirms “Neutral” Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)

Cantor Fitzgerald restated their neutral rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report released on Monday morning, Benzinga reports. The brokerage currently has a $1,015.00 target price on the biopharmaceutical company’s stock.

A number of other brokerages have also weighed in on REGN. Truist Financial reissued a buy rating and issued a $1,200.00 price target (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. Royal Bank of Canada restated an outperform rating and set a $1,250.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, September 5th. Piper Sandler upped their price target on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an overweight rating in a research note on Friday, August 23rd. Canaccord Genuity Group reiterated a buy rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Finally, TD Cowen boosted their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a buy rating in a report on Tuesday, July 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $1,111.30.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $1,138.81 on Monday. The stock has a market capitalization of $125.48 billion, a P/E ratio of 33.64, a price-to-earnings-growth ratio of 3.97 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals has a 1 year low of $769.19 and a 1 year high of $1,211.20. The firm has a 50 day moving average of $1,129.45 and a 200-day moving average of $1,029.70.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter in the previous year, the firm earned $8.79 earnings per share. The business’s revenue was up 12.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.8 EPS for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the transaction, the director now directly owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. Insiders have sold a total of 10,026 shares of company stock valued at $11,498,705 over the last 90 days. 7.48% of the stock is owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in REGN. Gilbert & Cook Inc. lifted its stake in Regeneron Pharmaceuticals by 8.3% in the 4th quarter. Gilbert & Cook Inc. now owns 1,907 shares of the biopharmaceutical company’s stock valued at $1,675,000 after purchasing an additional 146 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 45.2% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,188 shares of the biopharmaceutical company’s stock worth $1,043,000 after acquiring an additional 370 shares during the last quarter. Avantax Advisory Services Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 23.0% during the 4th quarter. Avantax Advisory Services Inc. now owns 1,001 shares of the biopharmaceutical company’s stock worth $879,000 after acquiring an additional 187 shares during the last quarter. Financial Advocates Investment Management raised its stake in Regeneron Pharmaceuticals by 25.6% in the 4th quarter. Financial Advocates Investment Management now owns 393 shares of the biopharmaceutical company’s stock valued at $345,000 after acquiring an additional 80 shares during the period. Finally, TrinityPoint Wealth LLC lifted its holdings in Regeneron Pharmaceuticals by 4.8% during the 4th quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 12 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.